Introduction
Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms ranging from indolent conditions with a near-normal life expectancy to forms approaching acute myeloid leukemia (AML). 1 The World Health Organization (WHO) classification of myeloid neoplasms 2 represents a very useful tool for defining the different subtypes, and provides also prognostic information. 3 Additional disease-related factors of considerable prognostic relevance include cytogenetic abnormalities, 4 degree of bone marrow failure, i.e., number and severity of peripheral cytopenias, and bone marrow fibrosis. 5 In order to evaluate the prognosis of the individual patient with MDS, several prognostic scoring systems have been developed. They include the International Prognostic Scoring System (IPSS), 6 the WHO classification-based prognostic scoring system (WPSS), 7 and the MD Anderson Prognostic Scoring System (MPSS). 8 These prognostic models have advantages and limitations that have been analyzed by us elsewhere.
9, 10
The WPSS is able to classify patients into five risk groups showing different survivals and probabilities of leukemic evolution, and can be applied at any time during followup. Although it supports the evidence-based 1 and also intuitive notion that the need for red cell transfusions predicts for a worse prognosis, 11 the use of transfusion dependency has been criticized as a too subjective criterion. 12 The use of hemoglobin thresholds would clearly overcome this limitation, but the relationship between degree of anemia and clinical outcome in MDS is currently poorly defined. A re-analysis of the international MDS risk analysis workshop (IMRAW) indicated that hemoglobin levels lower than 10 g/dL had additive prognostic value to IPSS in the low-risk groups. 13 However, studies of the Düsseldorf MDS registry 14, 15 had previously shown that hemoglobin values lower than or equal to 9 g/dL represented an independent negative prognostic factor.
In this work, we studied the relationship between degree of anemia and clinical outcome in MDS patients, and integrated the definition of severe anemia into a refined WPSS.
Design and Methods
These investigations were approved by the local Ethics Committees and the procedures followed were in accordance with the Helsinki Declaration of 1975, as revised in 2000.
Patients
We studied 840 consecutive patients diagnosed with MDS at the Fondazione IRCCS Red blood cell transfusion-dependency was defined as the absence of an interval longer than 28 days free from RBC transfusion over a surveillance period of 8 weeks:
this represents approximately a need of at least one unit of RBC per month. Cardiac disease was defined according to Sorror et al, 19 and included coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart failure, myocardial infarction or ejection fraction lower than or equal to 50%.
Statistical analyses
Numerical variables are summarized by median and range; categorical variable are described with count and relative frequency (%) of subjects in each category.
Comparison of numerical variables between groups was carried out using a nonparametric approach (Mann-Whitney test or Kruskall Wallis ANOVA).
Comparison In order to further investigate the impact of anemia on outcome we analyzed the relationship between hemoglobin levels and extra-hematological comorbidity and causes of NLD. As previously reported, one or more comorbidities were present at diagnosis in 455 out of 840 (54%) patients. 22 Cardiac disease was the most frequently observed comorbidity: it was noticed in 211 of 840 patients (25%) at the time of diagnosis whereas in 79 it occurred during the follow-up and. Cardiac disease included congestive heart failure (19%), coronary artery disease or myocardial infarction (8%), arrhythmia (7%), heart valve disease (2% 
Integration of the definition of severe anemia into the WPSS
We first investigated whether the sex-specific hemoglobin thresholds identified as having a significant prognostic value in multivariable analysis, i.e., hemoglobin lower than 9 g/dL in males and lower than 8 g/dL in females, could be as effective as Based on the above analyses, we refined the original WPSS 7 as reported in Table 2 .
As shown in Figure 3 and Table 3 , a landmark analysis at fixed time point from the diagnosis (6, 12, 24, 36, 60 months) showed that the refined WPSS was able to identify five risk groups with clearly different survivals.
Discussion
The working hypothesis that anemia, an MDS-related factor, may interact with cardiac disease, present as comorbid condition in a significant portion of MDS patients, thus negatively influencing the patient's outcome, is supported by several observations. In prospective population-based study of all 65 to 84 year old residents in a small Italian town, risks of mortality and hospitalization were significantly higher among mildly anemic elderly subjects compared with non-anemic ones. 23 Moreover, chronic heart failure is often associated with anemia of chronic disease, 24 and the presence of persistent anemia confers poorest survival in these patients. 25 In a metaanalysis of more than 150,000 patients with chronic heart failure, 26 anemia was present in one-third of the population studied and represented an independent risk prognosticator for mortality.
In this study we identified sex-specific hemoglobin thresholds that are independently associated with significant morbidity and mortality in MDS. In fact, male and female patients with hemoglobin lower than 9 and 8 g/dL, respectively, were found to be at higher risk of morbidity and mortality, mainly due to an increased risk of cardiac complications. Despite some discrepancy among studies in the reported prevalence, cardiac events have been identified as a major extra-hematological comorbidity and cause of death in patients with MDS. [27] [28] [29] [30] [31] [32] Our finding confirms previous observations of the Düsseldorf registry 14, 15 and expands our previous finding that transfusiondependency, an indicator of severe symptomatic anemia, is associated with an increased probability of cardiac death. 3, 7 We also found a significant interaction between severe anemia and cardiac disease on the risk of NLD, suggesting that cardiac comorbidity not only has an additive detrimental effect per se but also interacts with anemia in worsening the clinical course of the disease. 22 In addition, high serum ferritin levels were associated with a significantly higher risk of NLD in transfusion-dependent patients belonging to the low and intermediate WPSS risk groups. In particular, patients with serum ferritin levels higher than 3000 ng/mL were found to have a high risk of cardiac complications.
The WPSS accounts for WHO categories, cytogenetic abnormalities and red cell transfusion dependency. Although the prognostic value of this latter parameter was shown in both single center 7 and population-based studies, 30 and was also adopted by the Food and Drug Administration for approval of drugs for treatment of low-risk MDS (i.e., lenalidomide and 5-azacytidine), the use of transfusion dependency has been considered as a too subjective criterion. 12 The analysis performed in this study allowed us to identify hemoglobin thresholds that are independently associated with significant morbidity and mortality and are as effective as transfusion dependency in the prognostic assessment of MDS patients. In addition, in this study we adopted a more stringent definition of transfusion-dependency with respect to our previous proposal, 7 defining transfusion-dependency as the absence of a period free from transfusion longer than 28 days over a surveillance period of 8 weeks. The concordance shown in this study between this definition of transfusion dependency and that of severe anemia (hemoglobin level lower than 9 g/dL in males and 8 g/dL in females) supports its adoption. More generally, the use of sex-specific hemoglobin thresholds in combination with this stringent definition of transfusion dependency in the WPSS now provides an objective criterion for accounting for severe anemia in MDS patients.
The other potential significant limitation of WPSS was considered to be multilineage dysplasia. 12 We previously showed that, within MDS patients without excess of blasts, there was a significant difference in OS between those with unilineage dysplasia and those with multilineage dysplasia (median survival 108 vs 49 months). 3 The 2008 WHO classification of MDS 18 has reaffirmed the prognostic relevance of distinguishing between unilineage dysplasia, mainly involving the erythroid lineage, and multilineage dysplasia. Therefore, risk assessment in MDS should consider this parameter irrespective of the fact that its definition requires considerable expertise. 10 We and others reported that treatment of anemia in MDS with erythropoietin in selected patients has a positive impact on outcome, 33, 34 suggesting that preventing or adequately treating symptomatic anemia in MDS may results in a survival benefit.
The findings of this study suggest that once symptomatic anemia occurs in MDS patients with cardiac disease, an optimal management is mandatory in order to limit the negative interaction between anemia and cardiac disease. If none of the medical treatments is effective, a transfusion regimen able to maintaining pre-transfusion hemoglobin levels above 9 g/dL in males and above 8 g/dL in females should be adopted.
The negative impact of severe anemia on the outcome of patients with MDS should be carefully considered when planning delayed treatment strategies such as allogeneic stem cell transplantation in patients belonging to the low WPSS risk groups. 35, 36 In fact, patients developing severe anemia have a significantly higher risk of developing also cardiac disease, whose occurrence might affect their eligibility to allogeneic transplantation. 37 In conclusion, severe anemia should be considered as a major criterion for deciding type and timing of intervention in MDS patients. 38 The refined WPSS illustrated in Table 2 allows clinicians to account for the severity of anemia and may therefore be used for implementing therapeutic strategies aimed to increase hemoglobin levels in MDS patients.
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